"When Offered to Participate": A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
13
07
2020
revised:
26
08
2020
accepted:
21
09
2020
pubmed:
7
10
2020
medline:
30
9
2021
entrez:
6
10
2020
Statut:
ppublish
Résumé
Patient participation in clinical trials is vital for knowledge advancement and outcomes improvement. Few adult cancer patients participate in trials. Although patient. decision-making about trial participation has been frequently examined, the participation rate for patients actually offered a trial is unknown. A systematic review and meta-analysis using 3 major search engines was undertaken. We identified studies from January 1, 2000, to January 1, 2020, that examined clinical trial participation in the United States. Studies must have specified the numbers of patients offered a trial and the number enrolled. A random effects model of proportions was used. All statistical tests were 2-sided. We identified 35 studies (30 about treatment trials and 5 about cancer control trials) among which 9759 patients were offered trial participation. Overall, 55.0% (95% confidence interval [CI] = 49.4% to 60.5%) of patients agreed to enroll. Participation rates did not differ between treatment (55.0%, 95% CI = 48.9% to 60.9%) and cancer control trials (55.3%, 95% CI = 38.9% to 71.1%; P = .98). Black patients participated at similar rates (58.4%, 95% CI = 46.8% to 69.7%) compared with White patients (55.1%, 95% CI = 44.3% to 65.6%; P = .88). The main reasons for nonparticipation were treatment choice or lack of interest. More than half of all cancer patients offered a clinical trial do participate. These findings upend several conventional beliefs about cancer clinical trial participation, including that Black patients are less likely to agree to participate and that patient decision-making is the primary barrier to participation. Policies and interventions to improve clinical trial participation should focus more on modifiable systemic structural and clinical barriers, such as improving access to available trials and broadening eligibility criteria.
Sections du résumé
BACKGROUND
Patient participation in clinical trials is vital for knowledge advancement and outcomes improvement. Few adult cancer patients participate in trials. Although patient.
decision-making about trial participation has been frequently examined, the participation rate for patients actually offered a trial is unknown.
METHODS
A systematic review and meta-analysis using 3 major search engines was undertaken. We identified studies from January 1, 2000, to January 1, 2020, that examined clinical trial participation in the United States. Studies must have specified the numbers of patients offered a trial and the number enrolled. A random effects model of proportions was used. All statistical tests were 2-sided.
RESULTS
We identified 35 studies (30 about treatment trials and 5 about cancer control trials) among which 9759 patients were offered trial participation. Overall, 55.0% (95% confidence interval [CI] = 49.4% to 60.5%) of patients agreed to enroll. Participation rates did not differ between treatment (55.0%, 95% CI = 48.9% to 60.9%) and cancer control trials (55.3%, 95% CI = 38.9% to 71.1%; P = .98). Black patients participated at similar rates (58.4%, 95% CI = 46.8% to 69.7%) compared with White patients (55.1%, 95% CI = 44.3% to 65.6%; P = .88). The main reasons for nonparticipation were treatment choice or lack of interest.
CONCLUSIONS
More than half of all cancer patients offered a clinical trial do participate. These findings upend several conventional beliefs about cancer clinical trial participation, including that Black patients are less likely to agree to participate and that patient decision-making is the primary barrier to participation. Policies and interventions to improve clinical trial participation should focus more on modifiable systemic structural and clinical barriers, such as improving access to available trials and broadening eligibility criteria.
Identifiants
pubmed: 33022716
pii: 5918345
doi: 10.1093/jnci/djaa155
pmc: PMC7936064
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
244-257Subventions
Organisme : NCI NIH HHS
ID : UG1 CA189974
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
Oncol Nurs Forum. 2011 Sep;38(5):542-52
pubmed: 21875841
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):770-777
pubmed: 28244413
Contemp Clin Trials. 2013 Jan;34(1):1-9
pubmed: 23000081
Res Synth Methods. 2010 Apr;1(2):97-111
pubmed: 26061376
J Cancer Educ. 2015 Dec;30(4):743-8
pubmed: 25608719
Clin Lung Cancer. 2013 Jan;14(1):14-8
pubmed: 22591607
JAMA Netw Open. 2018 Aug 3;1(4):e181235
pubmed: 30646114
J Natl Cancer Inst. 1996 Jun 19;88(12):812-6
pubmed: 8637047
Cancer. 2005 Feb 1;103(3):483-91
pubmed: 15597407
J Natl Compr Canc Netw. 2010 Dec;8(12):1343-51
pubmed: 21147901
JAMA Oncol. 2019 Mar 1;5(3):326-333
pubmed: 30629092
Oncologist. 2012;17(9):1180-90
pubmed: 22723506
J Clin Oncol. 2002 Apr 15;20(8):2109-17
pubmed: 11956272
JAMA Oncol. 2019 Aug 15;:e191870
pubmed: 31415071
J Clin Oncol. 2008 Jun 1;26(16):2666-73
pubmed: 18509178
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Clin Oncol. 2017 Nov 20;35(33):3737-3744
pubmed: 28968170
JCO Oncol Pract. 2020 Mar;16(3):125-127
pubmed: 32074016
Trials. 2012 Dec 10;13:237
pubmed: 23227880
J Oncol Pract. 2014 Mar;10(2):e73-80
pubmed: 24424313
Cancer. 2014 Mar 15;120(6):877-84
pubmed: 24327389
J Clin Oncol. 2004 Jun 1;22(11):2046-52
pubmed: 15082724
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1087-90
pubmed: 14578147
J Clin Oncol. 2001 Mar 15;19(6):1728-33
pubmed: 11251003
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Gynecol Oncol. 2004 Aug;94(2):368-74
pubmed: 15297174
Med Oncol. 2019 Mar 6;36(4):34
pubmed: 30840157
J Comp Eff Res. 2015 Mar;4(2):133-45
pubmed: 25825842
J Clin Oncol. 2003 Jun 15;21(12):2268-75
pubmed: 12805325
Appl Nurs Res. 2013 Aug;26(3):133-5
pubmed: 23490340
Soc Sci Med. 1991;33(5):569-77
pubmed: 1962228
JAMA. 2020 May 26;323(20):2005-2006
pubmed: 32282023
JAMA Oncol. 2015 Dec;1(9):1303-10
pubmed: 26448610
MMWR Surveill Summ. 2017 Jul 07;66(14):1-13
pubmed: 28683054
Gynecol Oncol. 2015 Jul;138(1):101-8
pubmed: 25937529
J Clin Oncol. 2004 Feb 15;22(4):730-4
pubmed: 14966098
JNCI Cancer Spectr. 2020 Apr 24;4(4):pkaa034
pubmed: 32704619
Clin Trials. 2012 Dec;9(6):788-97
pubmed: 23033547
Cancer Control. 2016 Oct;23(4):327-337
pubmed: 27842322
Gynecol Oncol. 2017 Sep;146(3):465-469
pubmed: 28689668
J Natl Med Assoc. 2002 Aug;94(8):666-8
pubmed: 12152921
J Clin Oncol. 2013 Feb 10;31(5):536-42
pubmed: 23295802
Cancer. 2008 Jan 15;112(2):228-42
pubmed: 18008363
Stat Med. 2001 Mar 30;20(6):825-40
pubmed: 11252006
J Natl Cancer Inst. 2002 Mar 6;94(5):334-57
pubmed: 11880473
Gynecol Oncol. 2014 Jul;134(1):60-7
pubmed: 24680770
J Health Care Poor Underserved. 2011 Aug;22(3):912-24
pubmed: 21841287
J Geriatr Oncol. 2011 Jan 1;2(1):18-24
pubmed: 21503272
J Clin Oncol. 2000 Mar;18(6):1203-11
pubmed: 10715289
Oncologist. 2018 Oct;23(10):1242-1249
pubmed: 29700209
J Am Coll Surg. 2010 Mar;210(3):261-70
pubmed: 20193888
Cancer. 2006 Jan 15;106(2):426-33
pubmed: 16353206
PLoS Med. 2006 Feb;3(2):e19
pubmed: 16318411
Cancer J. 2004 Sep-Oct;10(5):294-300
pubmed: 15530258
Health Commun. 2000;12(1):23-39
pubmed: 10938905
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Oncol Pract. 2016 Jan;12(1):67-8, e44-51
pubmed: 26265173
Med Decis Making. 2014 Jan;34(1):116-26
pubmed: 23897588
J Immigr Minor Health. 2017 Feb;19(1):120-129
pubmed: 26801931
J Natl Cancer Inst. 2019 Mar 1;111(3):245-255
pubmed: 30856272
J Epidemiol Community Health. 2013 Nov 1;67(11):974-8
pubmed: 23963506
J Racial Ethn Health Disparities. 2015 Jun;2(2):244-55
pubmed: 26557471
Res Synth Methods. 2019 Mar;10(1):83-98
pubmed: 30067315
Br J Cancer. 1999 Jun;80(8):1275-80
pubmed: 10376984
J Thorac Oncol. 2011 Jan;6(1):98-102
pubmed: 21150469
Cancer. 2008 Jan 1;112(1):212-9
pubmed: 18008353
Oncologist. 2013;18(12):1315-20
pubmed: 24153239